{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+weeks+24+-+48",
    "query": {
      "intervention": "Placebo - weeks 24 - 48"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 140,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+-+weeks+24+-+48&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-24T10:35:48.278Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05194397",
      "title": "Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoblastic Leukemia",
        "Cancer Survivors",
        "Aplastic Anemia",
        "Myelodysplastic Syndromes",
        "Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "Nicotinamide Riboside",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Placebo",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "Exercise Intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT",
        "OTHER"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "10 Years to 30 Years"
      },
      "enrollment_count": 80,
      "start_date": "2023-02-23",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2025-12-04",
      "last_synced_at": "2026-09-24T10:35:48.278Z",
      "location_count": 3,
      "location_summary": "Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05194397"
    },
    {
      "nct_id": "NCT01180790",
      "title": "Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "ACH-0141625 (Sovaprevir)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Pegylated Interferon alpha-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2010-09",
      "completion_date": "2013-04",
      "has_results": true,
      "last_update_posted_date": "2023-08-30",
      "last_synced_at": "2026-09-24T10:35:48.278Z",
      "location_count": 15,
      "location_summary": "Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01180790"
    },
    {
      "nct_id": "NCT00722098",
      "title": "Comparison Study of Dendritic Cell Vaccine With and Without Cyclophosphamide to Treat Stage IV Melanoma Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Melanoma Stage IV"
      ],
      "interventions": [
        {
          "name": "DC Vaccine & Cyclophosphamide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "DC Vaccine & Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Baylor Research Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 9,
      "start_date": "2008-06",
      "completion_date": "2012-07",
      "has_results": false,
      "last_update_posted_date": "2013-07-08",
      "last_synced_at": "2026-09-24T10:35:48.278Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00722098"
    },
    {
      "nct_id": "NCT00603304",
      "title": "Complementary and Alternative Medicine for Urological Symptoms(CAMUS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Urological"
      ],
      "interventions": [
        {
          "name": "Saw Palmetto - first 24 weeks",
          "type": "DRUG"
        },
        {
          "name": "Placebo - first 24 weeks",
          "type": "DRUG"
        },
        {
          "name": "Saw Palmetto - weeks 24 - 48",
          "type": "DRUG"
        },
        {
          "name": "Placebo - weeks 24 - 48",
          "type": "DRUG"
        },
        {
          "name": "Saw Palmetto - weeks 48 - 72",
          "type": "DRUG"
        },
        {
          "name": "Placebo - weeks 48 - 72",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "45 Years and older · Male only"
      },
      "enrollment_count": 369,
      "start_date": "2008-02",
      "completion_date": "2010-12",
      "has_results": true,
      "last_update_posted_date": "2012-10-12",
      "last_synced_at": "2026-09-24T10:35:48.278Z",
      "location_count": 10,
      "location_summary": "Oakland, California • Aurora, Colorado • New Haven, Connecticut + 6 more",
      "locations": [
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00603304"
    },
    {
      "nct_id": "NCT00506415",
      "title": "Comparative Efficacy, Safety, and Tolerability of Rivastigmine 10 and 15 cm^2 Patch in Patients With Alzheimer's Disease (AD) Showing Cognitive Decline",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer Disease"
      ],
      "interventions": [
        {
          "name": "Rivastigmine 5 cm^2",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 10 cm^2",
          "type": "DRUG"
        },
        {
          "name": "Rivastigmine 15 cm^2",
          "type": "DRUG"
        },
        {
          "name": "Placebo to 15 cm^2 patch",
          "type": "DRUG"
        },
        {
          "name": "Placebo to 10 cm^2 patch",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "50 Years to 85 Years"
      },
      "enrollment_count": 1584,
      "start_date": "2007-06",
      "completion_date": "2011-05",
      "has_results": true,
      "last_update_posted_date": "2012-09-19",
      "last_synced_at": "2026-09-24T10:35:48.278Z",
      "location_count": 65,
      "location_summary": "Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 61 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00506415"
    },
    {
      "nct_id": "NCT01271790",
      "title": "A Study of Response-Guided Duration of Combination Therapy With GS-9451, Pegasys® and Copegus® With and Without Tegobuvir (GS-9190) in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "Tegobuvir (GS-9190)",
          "type": "DRUG"
        },
        {
          "name": "GS-9451",
          "type": "DRUG"
        },
        {
          "name": "Pegasys®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Copegus®",
          "type": "DRUG"
        },
        {
          "name": "Tegobuvir placebo",
          "type": "DRUG"
        },
        {
          "name": "GS-9451 placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 245,
      "start_date": "2010-10",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2014-02-06",
      "last_synced_at": "2026-09-24T10:35:48.278Z",
      "location_count": 85,
      "location_summary": "Dothan, Alabama • Montgomery, Alabama • Phoenix, Arizona + 62 more",
      "locations": [
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01271790"
    },
    {
      "nct_id": "NCT07486934",
      "title": "Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Myotonic Dystrophy Type 1 (DM1)",
        "DM1",
        "Myotonic Dystrophy",
        "Steinert Disease",
        "Steinert"
      ],
      "interventions": [
        {
          "name": "zeleciment basivarsen (DYNE-101)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dyne Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2026-05-14",
      "completion_date": "2029-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-03",
      "last_synced_at": "2026-09-24T10:35:48.278Z",
      "location_count": 10,
      "location_summary": "La Jolla, California • Los Angeles, California • Palo Alto, California + 7 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07486934"
    },
    {
      "nct_id": "NCT07733765",
      "title": "A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Alopecia Areata"
      ],
      "interventions": [
        {
          "name": "Ritlecitinib 100 mg",
          "type": "DRUG"
        },
        {
          "name": "Ritlecitinib 50 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 336,
      "start_date": "2026-07-30",
      "completion_date": "2028-04-26",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-09-24T10:35:48.278Z",
      "location_count": 17,
      "location_summary": "Encinitas, California • Miami, Florida • Skokie, Illinois + 11 more",
      "locations": [
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Skokie",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07733765"
    },
    {
      "nct_id": "NCT00425932",
      "title": "Impact of Rituximab on MRI Evidence of Disease Activity in Patients With Moderate to Severe Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Rituximab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Gaylis, Norman B., M.D.",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 60,
      "start_date": "2007-02",
      "completion_date": "2012-11",
      "has_results": false,
      "last_update_posted_date": "2013-08-22",
      "last_synced_at": "2026-09-24T10:35:48.278Z",
      "location_count": 6,
      "location_summary": "Fort Lauderdale, Florida • Hollywood, Florida • Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Fort Lauderdale",
          "state": "Florida"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Wichita",
          "state": "Kansas"
        },
        {
          "city": "Oklahoma City",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00425932"
    },
    {
      "nct_id": "NCT04640077",
      "title": "A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alzheimer Disease",
        "Dementia",
        "Brain Diseases",
        "Central Nervous System Diseases",
        "Cognitive Impairment"
      ],
      "interventions": [
        {
          "name": "No Intervention",
          "type": "OTHER"
        },
        {
          "name": "donanemab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "60 Years to 90 Years"
      },
      "enrollment_count": 95,
      "start_date": "2020-11-23",
      "completion_date": "2024-02-27",
      "has_results": true,
      "last_update_posted_date": "2025-06-13",
      "last_synced_at": "2026-09-24T10:35:48.278Z",
      "location_count": 23,
      "location_summary": "Phoenix, Arizona • Irvine, California • Bradenton, Florida + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Merritt Island",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04640077"
    }
  ]
}